Company Filing History:
Years Active: 2018-2019
Title: Katja Haike: Innovator in Pharmaceutical Research
Introduction
Katja Haike is a prominent inventor based in Potsdam, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of lymphomas. With a focus on innovative compounds, her work has the potential to impact many lives.
Latest Patents
Katja Haike holds 2 patents related to the use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating various types of lymphomas. Her patents describe pharmaceutical combinations and compositions that include a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or a salt thereof, along with additional active agents. These combinations may be effective in treating non-Hodgkin's lymphoma (NHL), including various forms such as follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Career Highlights
Katja Haike is currently associated with Bayer Pharma Aktiengesellschaft, where she continues to advance her research in oncology. Her innovative approaches to drug development have garnered attention in the pharmaceutical industry.
Collaborations
Throughout her career, Katja has collaborated with notable colleagues, including Ningshu Liu and Juliane Paul. These partnerships have contributed to her success in developing effective treatments for complex medical conditions.
Conclusion
Katja Haike's work exemplifies the impact of innovation in the pharmaceutical industry. Her contributions to lymphoma treatment highlight the importance of research and collaboration in advancing medical science.